Ajenat Pharmaceuticals
United States Updated 9 July 2026
Ajenat Pharmaceuticals is a finished-dose manufacturer based in United States. It appears in 13 regulatory filings across 1 regulator, without an active US DMF or CEP on file. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 7 February 2025 as NAI.
2
registered plants
2 with an FDA FEI number
13
filings
across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 7 February 2025 NAI US FDA
- 16 August 2024 VAI US FDA
- 4 November 2022 NAI US FDA
- 24 May 2019 NAI US FDA
- 1 March 2018 VAI US FDA
- 13 May 2016 VAI US FDA
- 21 November 2014 NAI US FDA
- 3 February 2014 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Tampa, United States | 3027254816 |
| Largo, United States | 3033007964 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | 13 | 1 |
Comparing suppliers?
Choose your molecules and target markets. Ajenat Pharmaceuticals comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was NAI, on 7 February 2025.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates